Meyka Pro banner
Precigen, Inc.

Precigen, Inc. Fundamental Analysis (NASDAQ: PGEN)

PGENNASDAQ
HealthcareBiotechnology
$7.70
$0.08(1.03%)
U.S. Market opens in 9h 56m

Precigen, Inc. Fundamental Analysis (NASDAQ: PGEN)

Precigen, Inc. (NASDAQ: PGEN) shows weak financial fundamentals with a PE ratio of -6.82, profit margin of -1.84%, and ROE of -4.98%. The company generates $0.1B in annual revenue with weak year-over-year growth of 1.47%.

Key Strengths

PEG Ratio0.02
Current Ratio4.58

Areas of Concern

ROE-4.98%
Operating Margin-46.08%
Cash Position1.39%
We analyze PGEN's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -606.8/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-606.8/100

We analyze PGEN's fundamental strength across five key dimensions:

Efficiency Score

Weak

PGEN struggles to generate sufficient returns from assets.

ROA > 10%
-92.61%

Valuation Score

Excellent

PGEN trades at attractive valuation levels.

PE < 25
-6.82
PEG Ratio < 2
0.02

Growth Score

Weak

PGEN faces weak or negative growth trends.

Revenue Growth > 5%
1.47%
EPS Growth > 10%
-2.00%

Financial Health Score

Moderate

PGEN shows balanced financial health with some risks.

Debt/Equity < 1
2.26
Current Ratio > 1
4.58

Profitability Score

Weak

PGEN struggles to sustain strong margins.

ROE > 15%
-498.32%
Net Margin ≥ 15%
-1.84%
Positive Free Cash Flow
No

Key Financial Metrics

Is PGEN Expensive or Cheap?

P/E Ratio

PGEN trades at -6.82 times earnings. This suggests potential undervaluation.

-6.82

PEG Ratio

When adjusting for growth, PGEN's PEG of 0.02 indicates potential undervaluation.

0.02

Price to Book

The market values Precigen, Inc. at 63.23 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

63.23

EV/EBITDA

Enterprise value stands at -18.42 times EBITDA. This is generally considered low.

-18.42

How Well Does PGEN Make Money?

Net Profit Margin

For every $100 in sales, Precigen, Inc. keeps $-1.84 as profit after all expenses.

-1.84%

Operating Margin

Core operations generate -46.08 in profit for every $100 in revenue, before interest and taxes.

-46.08%

ROE

Management delivers $-4.98 in profit for every $100 of shareholder equity.

-4.98%

ROA

Precigen, Inc. generates $-92.61 in profit for every $100 in assets, demonstrating efficient asset deployment.

-92.61%

Following the Money - Real Cash Generation

Operating Cash Flow

Precigen, Inc. generates limited operating cash flow of $-114.04M, signaling weaker underlying cash strength.

$-114.04M

Free Cash Flow

Precigen, Inc. generates weak or negative free cash flow of $-115.70M, restricting financial flexibility.

$-115.70M

FCF Per Share

Each share generates $-0.32 in free cash annually.

$-0.32

FCF Yield

PGEN converts -4.22% of its market value into free cash.

-4.22%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-6.82

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.02

vs 25 benchmark

P/B Ratio

Price to book value ratio

63.23

vs 25 benchmark

P/S Ratio

Price to sales ratio

32.11

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

2.26

vs 25 benchmark

Current Ratio

Current assets to current liabilities

4.58

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-4.98

vs 25 benchmark

ROA

Return on assets percentage

-0.93

vs 25 benchmark

ROCE

Return on capital employed

-0.28

vs 25 benchmark

How PGEN Stacks Against Its Sector Peers

MetricPGEN ValueSector AveragePerformance
P/E Ratio-6.8230.58 Better (Cheaper)
ROE-498.32%579.00% Weak
Net Margin-183.98%24148.00% Weak
Debt/Equity2.260.52 Weak (High Leverage)
Current Ratio4.585.66 Strong Liquidity
ROA-92.61%-58.00% (disorted) Weak

PGEN outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Precigen, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-83.40%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

19.41%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

37.48%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ